China Gender-affirming Hormone Therapy Study
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Apr 1, 2022
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
The China Gender-affirming Hormone Therapy Study is researching how hormone therapy affects transgender individuals in China, where there is limited information on this topic. The trial aims to understand both the physical and mental health impacts of gender-affirming hormone therapy (GAHT) for transgender people who wish to begin this treatment. By participating, individuals can help improve the knowledge and care available for the transgender community in China.
To take part in this study, participants need to be transgender men or women, aged between 18 and 40, and should want to start hormone therapy. They should not have undergone any previous gender-affirming treatments or surgeries. Throughout the study, participants can expect to share their experiences and receive support as researchers gather important information to better understand the effects of hormone therapy. It’s important to note that some people may not be eligible if they have certain medical conditions or are currently taking specific medications.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Transgender men and women
- • Meet criteria of Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) for gender dysphoria
- • Aged between 18 to 40 years
- • People desire to start the GAHT
- • No previous history of gender-affirming interventions
- • Having full ability to make informed consent
- • Dextromanual
- Exclusion Criteria:
- • Disorders of sex development
- • Who has fertility demand but have not made fertility preservation
- • With contradictions of GAHT
- • Comorbid diseases are not under control
- • Alcohol or drug abuse
- • Hormonal and chromosomal disorders
- • History of gender affirming surgery
- • Current psychiatric disorders
- • History of brain trauma or neurological pathologies
- • Current use of medications with psychotropic effects within two weeks (antipsychotic or antiepileptic agents, lithium, benzodiazepines or opioid analgesics)
- • Claustrophobia
- • Implanted metal and medical devices (pacemakers, ceramic teeth, etc.),
- • Tattoos or eyebrow tattooing (heavy metal dye)
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Peking, Beijing, China
Patients applied
Trial Officials
Tianpei Hong, PhD., M.D.
Principal Investigator
Department of Endocrinology and Metabolism, Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials